Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix Inc., sold 3,296 shares of the company’s common stock on August 24, 2026, for approximately $35,530 under a prearranged 10b5-1 trading plan adopted on April 9, 2024.
The sale occurred at weighted average prices ranging from $10.6425 to $10.9125 per share, with a final average of $10.78. The transaction was executed to cover tax obligations arising from the vesting of restricted stock units on August 22, 2026, and did not reflect discretionary trading activity.
Following the disposition, Heier retains a beneficial ownership of 318,326 shares of Ocular Therapeutix common stock, including 1,272 shares acquired through the company’s employee stock purchase plan on June 30, 2026.
Ocular Therapeutix’s stock was last quoted near $10.77, with call options trading at 9,882 contracts. Analyst targets for the company’s shares range from $18 to $34, with H.C. Wainwright raising its price target to $25 and assigning a 75% probability of approval for the company’s lead candidate AXPAXLI.
Citizens analysts maintained a $34 target and projected second-quarter 2026 revenue of $12 million from the company’s Dex product. The company plans to submit a New Drug Application for AXPAXLI in the fourth quarter of 2026, targeting wet age-related macular degeneration, following a Type C meeting with the U.S. FDA.
The filing follows the failure of a Phase 3 pivotal study for a competing wet AMD treatment by EyePoint Pharmaceuticals, which analysts noted created a favorable competitive backdrop for Ocular Therapeutix.
